Dr. McGovern serves on the National Scientific Advisory Committee for the Crohn’s and Colitis Foundation as well as the steering committees of the National and International IBD Genetics Consortia. He also chairs the CCFA local advisory medical committee. Dr. McGovern serves on the editorial board for the IBD Journal. He has been elected a member of the American Society for Clinical Investigation (ASCI) and also the International Organization for the Study of IBD (IOIBD). Dr. McGovern’s group is funded by the NIH to study the effect of genetics on the susceptibility to and natural history of IBD in diverse populations. Dr McGovern’s group analyze multi’-omic’ datasets to identify potential biomarkers and therapeutic targets of IBD that ‘feed’ the Drug Development Unit he co-directs. His group also have a significant interest in the pharmacogenetics of therapies used in IBD. Extending these studies to diverse populations including African-Americans, Hispanics, and the Ashkenazi Jewish population is a major focus of his group. His group is also funded by the Crohn’s and Colitis Foundation, The Litwin Foundation, and the Helmsley Charitable Trust. Dr. McGovern’s group have published approximately 150 peer-reviewed papers in journals including Nature, Science, Cell, Nature Genetics, The Lancet, and Gastroenterology.